Vonafexor series
ENYO Pharma is advancing its pipeline with Vonafexor series for diseases with impaired kidney function like Alport syndrome, CKD and MASH*.
Vonafexor (EYP001)
Vonafexor is a synthetic non-steroidal, non-bile acid farnesoid X receptor (FXR)** agonist. It activates FXR with a high selectivity compared to other nuclear receptors and does not display any activity on bile acid receptor TGR5.
This small molecule has a different structure compared to other FXR agonists and induces a differential set of target genes based on ligand binding patterns.
Vonafexor for diseases with impaired kidney function
Alport syndrome
A rare kidney disease, the second most common inherited kidney disease
- Pre-clinical studies: Pre-clinical studies in a severe Alport syndrome mouse model*** confirmed Vonafexor’s effects in this indication by strongly improving kidney morphology and remodeling, and renal function.
- Clinical study: The Phase 2 ALPESTRIA-1 clinical study is evaluating the safety, the tolerability and the benefit of three dose levels of the investigational drug Vonafexor on renal function and biomarkers in Alport syndrome patients. Learn more about ALPESTRIA-1 study
CKD
Chronic kidney disease, a disease with a gradual loss of kidney function
- Pre-clinical studies: Pre-clinical studies in a severe CKD mouse model*** show that both Vonafexor and its analog have a strong and significant curative effect on kidney biology after only 3 weeks of treatment, when compared to Ocaliva, Nidufexor and Losartan (SoC of CKD), on kidney morphology and remodeling, renal interstitial fibrosis and inflammation.
- Clinical study: Phase 2a study on NASH patients with F2-F3 liver fibrosis (LIVIFY study) shows that Vonafexor significantly improves kidney function parameters after 12 weeks of treatment.
MASH
Metabolic dysfunction-associated steatohepatitis, a liver disease evolving to CKD
- Pre-clinical studies: Preclinical studies have demonstrated Vonafexor’s efficacy in the Stelic mouse model (STAM(TM)) with significant positive impact on most of the MASH key parameters. It differentiates from other FXR agonists with a unique chemistry and PK/PD profile to possibly provide best-in-class therapeutic index.
- Clinical study: The Phase 2a LIVIFY study recently evaluated Vonafexor (EYP001) in patients with advanced NASH, i.e. a fibrosis stage F2 or F3. Positive results showed that Vonafexor decreases liver fibrosis and inflammation marker (fibroscan, cT1, …), reduces liver fat and weight, and improves liver enzymes and renal function in patients with suspected fibrotic NASH. As NASH increases the risk of kidney problems, these results support development of Vonafexor for patients suffering from diseases with impaired renal function. Ratziu et al. (2022)
* Metabolic dysfunction-associated steatohepatitis (MASH), previously named non-alcoholic steatohepatitis (NASH)
** FXR: farnesoid X receptor is a nuclear receptor mainly expressed in liver, kidney and gut. It is activated by bile acids and therefore regulates targeted genes involved in many biological processes as bile acid metabolism, inflammation, fibrosis, glucose and lipid metabolism.
*** In collaboration with Dr. Fabiola Terzi’s lab, Mecanisms and therapeutic strategies of chronic kidney disease,INEM, Paris, France
** FXR: farnesoid X receptor is a nuclear receptor mainly expressed in liver, kidney and gut. It is activated by bile acids and therefore regulates targeted genes involved in many biological processes as bile acid metabolism, inflammation, fibrosis, glucose and lipid metabolism.
*** In collaboration with Dr. Fabiola Terzi’s lab, Mecanisms and therapeutic strategies of chronic kidney disease,INEM, Paris, France
Key Opinion Leaders
Pr Myles Wolf, MD, MMSc
- Professor of Medicine and Chief of the Division of Nephrology at the Duke University School of Medicine, US
Pr Bertrand Knebelmann, MD, PhD
- Nephrologist in the adult nephrology-dialysis department of the Necker-Enfants Malades hospital in Paris and professor at the University of Paris-Descartes, Paris, France
Dr Fabiola Terzi, MD, PhD
- Director of the research Institut Necker-Enfants Malades (INEM) in Paris, France
https://www.institut-necker-enfants-malades.fr
Dr Naim Alkhouri, MD
- VP of Academic Affairs, Director of the Fatty Liver Program. Arizona Liver Health, Scottsdale, Arizona
Pr Jean-François Dufour, MD
- President Swiss NASH Foundation & Swiss Foundation against Liver Cancer
- Professor of Hepatology at the University Hospital of Bern in Bern, Switzerland
https://swissnashfoundation.org/
Pr Sven Francque, MD, PhD
- Chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp, Belgium
- Professor of Medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp in Belgium
https://swissnashfoundation.org/
Dr Stephen Harrison, MD
- Medical Director of Pinnacle Clinical Research, San Antonio, US
- Gastroenterologist/Hepatologist, specializing in Liver Disease
Pr Vlad Ratziu, MD, PhD
- Professeur at Sorbonne Université and Hospital Pitié Salpetrière, Paris, France
https://pitiesalpetriere.aphp.fr
Pr Nadarajah Sreeharan, MD, PhD
- Visiting Professor at King’s College and Fellow of the Royal Colleges of Physicians of London and the American College of Physicians, UK
- Formerly SVP and European Medical Director, GSK R&D, Officer of the Board of Examiners in Pharmaceutical Medicine at the Royal College of Physicians, and faculty to the Scholars in Clinical Science Program at the Harvard Medical School.
Latest Press Release 